| Cash Flow | 2025-09-28 | 2025-06-29 |
|---|---|---|
| Net loss | -1,001,100 | -268,100 |
| Depreciation and amortization | 329,500 | 217,400 |
| Goodwill impairment charge | 700,700 | 0 |
| Asset impairment charge | 9,700 | 0 |
| Stock-based compensation expense | 35,100 | 24,400 |
| Change in deferred tax assets and liabilities | -1,500 | -500 |
| Loss on extinguishment of debt | -5,100 | - |
| Asset write off related to restructuring, integration and other charges | 152,200 | 151,400 |
| Other non-cash, net | -1,500 | 14,300 |
| Accounts receivable | 88,700 | -24,700 |
| Inventories | 141,700 | 102,600 |
| Prepaid expenses and other current and non-current assets | 16,100 | 8,500 |
| Accounts payable | -15,900 | -23,500 |
| Accrued payroll and related expenses | -14,900 | -34,900 |
| Income taxes payable | 31,200 | 57,500 |
| Other current and non-current liabilities | -8,800 | -32,800 |
| Net cash (used for) provided by operating activities | -26,700 | 18,800 |
| Acquisitions of property, plant, equipment, investments and intangibles | 142,900 | 93,700 |
| Proceeds from government assistance allocated to fixed assets | 6,500 | 6,500 |
| Purchases of marketable securities | 0 | 0 |
| Proceeds from sale of marketable securities | 0 | 0 |
| Loan to lex diagnostics | 6,700 | 2,000 |
| Net cash used for investing activities | -143,100 | -89,200 |
| Proceeds from issuance of common stock | 6,000 | 3,100 |
| Short-term borrowings, net | 5,300 | 1,900 |
| Revolving credit facility, net | -98,000 | 192,000 |
| Proceeds from long-term borrowings, net of discount and debt issuance costs | 2,546,200 | - |
| Payments on long-term borrowings | 2,287,600 | 72,000 |
| Payments of tax withholdings related to vesting of stock-based awards | 5,000 | 4,100 |
| Net cash provided by financing activities | 166,900 | 120,900 |
| Effect of exchange rates on cash | 2,500 | 2,700 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -400 | 53,200 |
| Cash and cash equivalents at beginning of period | 98,500 | - |
| Cash and cash equivalents at end of period | 98,100 | - |
QuidelOrtho Corp (QDEL)
QuidelOrtho Corp (QDEL)